Advertisement
Advertisement
U.S. Markets open in 4 hrs 55 mins
Advertisement
Advertisement
Advertisement
Advertisement

Kinarus Therapeutics Holding AG (KNRS.SW)

Swiss - Swiss Delayed Price. Currency in CHF
0.0112-0.0028 (-20.00%)
As of 10:11AM CET. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0140
Open0.0140
Bid0.0112 x N/A
Ask0.0120 x N/A
Day's Range0.0112 - 0.0140
52 Week Range0.0082 - 0.0366
Volume1,714,737
Avg. Volume1,812,174
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est107.00
  • GlobeNewswire

    Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5

    Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5 Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg and Kinarus report new antiviral data of KIN001 against SARS-CoV-2 Omicron BA.2 and BA.5 subvariantsKINFAST Phase 2 trial of KIN001 in ambulatory COVID-19 patients is actively recruiting Basel, Switzerland, 6 December 2022 -- Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical com

  • GlobeNewswire

    Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001

    Method-of-use-patent covers KIN001 in ophthalmic diseasesFurther strengthens already granted KIN001 US composition of matter patent Basel, Switzerland, 22 November 2022. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announced today the receipt of a Notice of Allowability from the United States Patent and Trademark Office (USPTO) for US Patent Application No. 1

  • GlobeNewswire

    Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China

    Kinarus to explore partnerships in China to fund Phase 2 clinical trials of KIN001 and explore further business opportunitiesMultiple opportunities for KIN001 in indications with high unmet need are well-matched to the Chinese market Basel, Switzerland, 16 November 2022. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announced today that it has engaged Great He

Advertisement
Advertisement